1. Home
  2. BJDX vs CDT Comparison

BJDX vs CDT Comparison

Compare BJDX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluejay Diagnostics Inc.

BJDX

Bluejay Diagnostics Inc.

HOLD

Current Price

$1.99

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.93

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BJDX
CDT
Founded
2015
2019
Country
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BJDX
CDT
Price
$1.99
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
155.9K
234.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$55.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.37
52 Week High
$10.20
$6.00

Technical Indicators

Market Signals
Indicator
BJDX
CDT
Relative Strength Index (RSI) 46.21 35.49
Support Level $2.84 $0.99
Resistance Level $3.60 $1.15
Average True Range (ATR) 0.45 0.11
MACD -0.13 0.00
Stochastic Oscillator 6.53 7.73

Price Performance

Historical Comparison
BJDX
CDT

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: